WeVote
Log In

Bill

Bill

HF 703

Cancer imaging and clinical genetic testing coverage requirements provided.

2025-2026 Regular Session Introduced by Patty Acomb and 4 co-sponsors

HF 703 requires Minnesota health plans to cover medically necessary cancer imaging and clinical genetic testing, with access, cost-sharing, and provider guidelines.

Author added Elkins
#insurance-health
0
WeVote Research Nonpartisan
Bill Summary · HF 703

Summary of HF 703 (Minnesota, 2025-2026 Session)

Title

Cancer imaging and clinical genetic testing coverage requirements provided.

Primary Purpose

HF 703 aims to specify insurance coverage requirements related to cancer imaging services and clinical genetic testing. The bill sets forth conditions under which health plans must cover certain diagnostic imaging and genetic testing activities for cancer, potentially including criteria for when such services are covered, and the types of providers or settings eligible for coverage.

Note: The available information provided in the bill caption and action history does not include the full text or detailed provisions. The summary below reflects the bill’s stated focus on cancer imaging and clinical genetic testing coverage and the general structure of typical coverage-related legislation.

Key Provisions (Expected/Typical Coverage Elements)

While the exact statutory language is not provided here, bills of this type commonly include:

  • Coverage Mandates for Cancer Imaging

    • Reimbursement requirements for imaging modalities used in cancer screening, diagnosis, staging, and surveillance (e.g., mammography, MRI, CT, PET scans, ultrasound) when medically necessary.
    • Criteria or guidelines to determine medical necessity, such as adherence to recognized clinical guidelines or physician certification.
    • Parity with coverage for other medical conditions, ensuring no discrimination in imaging coverage.

  • Clinical Genetic Testing Coverage

    • Requirements for coverage of genetic tests that inform cancer risk assessment, diagnosis, prognosis, or treatment (e.g., BRCA1/BRCA2, Lynch syndrome panels, other hereditary cancer panels).
    • Conditions under which tests must be covered (e.g., when ordered by a licensed clinician, when tests are indicated by personal or family history, or when results influence treatment decisions).
    • Provisions regarding pre- and post-test genetic counseling where applicable.
    • Consideration of test modalities (e.g., sequencing, panel tests) and potential exclusions or limitations (e.g., age cutoffs, disease status).

  • Cost-Sharing and Network Provisions

    • Rules regarding copayments, coinsurance, or deductibles for covered imaging and genetic testing.
    • Requirements to provide in-network access or to cover out-of-network services when appropriate, or timelines to meet network adequacy standards.

  • Timelines and Administrative Processes

    • Effective dates or phase-in periods for implementation by insurers.
    • Requirements for timeliness of claim processing and prior authorization standards, if any.
    • Reporting or compliance obligations for health plans and possibly regulated entities.

  • Exclusions and Limitations

    • Any specified exceptions or situations where coverage does not apply (e.g., experimental or investigational tests, non-medically necessary procedures) as allowed by law.

  • Enforcement and Oversight

    • Mechanisms for enforcement, penalties for non-compliance, and guidance for dispute resolution.

Who Would be Affected

  • Health Insurance Plans regulated in Minnesota, including:
    • Fully insured and possibly self-insured (depending on applicable state law and any carve-outs) plans operating in Minnesota.
  • Covered Individuals:
    • Minnesota residents with policies that fall under the bill’s coverage requirements, including patients undergoing cancer imaging or clinical genetic testing.
  • Healthcare Providers:
    • Hospitals, clinics, radiology centers, and genetic testing laboratories that perform imaging and genetic testing and bill insurers.
  • Employers and Providers of Services:
    • Entities involved in delivering imaging and genetic testing services, and clinicians ordering such services.

Procedural and Timeline Aspects

  • Introductions and Sponsorship:
    • Introduced and referred to the Commerce Finance and Policy committee (2/13/2025).
    • Expanded sponsorship over time with additional authors: Engen, Falconer, Hemmingsen-Jaeger, Elkins, Acomb (dates noted in action history).
  • Amendments/Action History:
    • The bill’s action history shows ongoing author additions, indicating potential refinements during committee process.
  • Next Steps:
    • Awaiting committee hearings, potential amendments, and floor action before full passage.
    • If enacted, regulatory implementation would require insurers to align plans with the new coverage requirements by the bill’s effective date.

Notes for Readers

  • The summary focuses on the bill’s stated scope: coverage for cancer imaging and clinical genetic testing. For precise requirements, including specific medical necessity criteria, covered test panels, cost-sharing limits, and any exemptions, the bill’s full text and any amendments would provide definitive language.
  • If you represent a stakeholder (patient, provider, insurer), reviewing the current draft and committee amendments will be essential to understand the exact obligations and any transitional provisions.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.